Ebrahim Sadeghi-Najafabadi, MD
Rheumatology · Upland, CANPI 1205156866
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 1,035 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by Amgen at 25.2% of the total.
Across 1,035 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$5K
- AbbVie$5K
- Johnson & Johnson$2K
- Novartis$1K
- GSK$1K
- AstraZeneca$794
- plus $5K from 30 others
Across 48 payments — averaging $3943.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$93K
- GSK$52K
- AstraZeneca$45K
What the payments were for
- Food & beverage$20,81798%
- Education$3542%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 278 | $5,327 |
| AbbVie | 227 | $4,880 |
| Johnson & Johnson(2 entities) | 101 | $2,213 |
| Novartis | 108 | $1,486 |
| GSK | 50 | $1,009 |
| AstraZeneca(2 entities) | 35 | $794 |
| Mallinckrodt Hospital Products Inc. | 23 | $655 |
| Aurinia Pharma U.S., Inc. | 24 | $629 |
| Pfizer | 30 | $617 |
| E.r. Squibb & Sons, L.L.C. | 25 | $525 |
| Organon | 20 | $358 |
| Boehringer Ingelheim | 15 | $350 |
| Lilly USA, LLC | 16 | $291 |
| Radius Health, Inc. | 10 | $269 |
| Sanofi | 11 | $232 |
| Fresenius Kabi USA, LLC | 7 | $220 |
| Sobi, Inc | 7 | $173 |
| UCB, Inc. | 6 | $158 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $143 |
| Genentech USA, Inc. | 5 | $128 |
| Sandoz | 5 | $105 |
| Octapharma USA, Inc. | 2 | $84 |
| ANI Pharmaceuticals, Inc. | 3 | $84 |
| Cumberland Pharmaceuticals, Inc. | 3 | $80 |
| Azurity Pharmaceuticals, Inc. | 3 | $69 |
| Scilex Pharmaceuticals Inc. | 3 | $58 |
| Alvogen Inc | 3 | $50 |
| Bristol Myers Squibb | 2 | $45 |
| Fidia Pharma USA Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Medexus Pharma, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,171 in reported general payments places this provider in the 80th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 32 | $197,379 |
| Orencia ClickjectAbatacept | 29 | $179,699 |
| Enbrel SureclickEtanercept | 18 | $142,009 |
| Humira(Cf) PenAdalimumab | 19 | $136,414 |
| XeljanzTofacitinib Citrate | 17 | $110,847 |
| KevzaraSarilumab | 14 | $59,780 |
| Actemra ActpenTocilizumab | 12 | $56,637 |
| ProliaDenosumab | 32 | $52,570 |
| RasuvoMethotrexate/Pf | 36 | $18,959 |
| Hydroxychloroquine Sulfate | 260 | $10,483 |
| Epinephrine | 15 | $4,480 |
| MethotrexateMethotrexate Sodium | 181 | $4,197 |
| Zoledronic AcidZoledronic Acid/Mannitol-Water | 18 | $1,785 |
| Gabapentin | 126 | $1,144 |
| Diclofenac Sodium | 17 | $1,078 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $4,880 | $197,37932 claims |
| PfizerXeljanz | $617 | $110,84717 claims |
| SanofiKevzara | $232 | $59,78014 claims |
| AmgenProlia | $5,327 | $52,57032 claims |
| Medexus Pharma, Inc.Rasuvo | $16 | $18,95936 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $58 | $69918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 808 rheumatology providers in California.
Other rheumatology in Upland
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.